Aptose Biosciences Inc's stock remains stable this week as the company transitions following its acquisition.
Aptose Biosciences Inc (APS.TO) has seen no change in its stock price this week, maintaining a close of C$2.40. The company recently completed its acquisition by Hanmi Pharmaceutical, which may influence its trading dynamics moving forward.
Investor takeaway: Investors should consider the implications of the acquisition on Aptose's future operations and stock performance. With a stable price action and no major news, the focus may shift to how the integration with Hanmi Pharmaceutical unfolds.
Advertisement
Aptose Biosciences Inc
APS.TO
APS.TO
Aptose Biosciences Inc
WealthAwesomeAdvertisement
Market cap
$6.13M
52W high
$2.59
52W low
$1.41
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering APS
Wall Street analysts forecast APS stock price to fall 1.7% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.36
-1.7% Upside
Current Price
C$2.40
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APS's historical volatility
30-Day Vol
52.7%
Annualized
90-Day Vol
48.9%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$2.40
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.40 | C$2.00 – C$2.88 |
| 60 trading days | C$2.40 | C$1.86 – C$3.10 |
| 90 trading days | C$2.40 | C$1.75 – C$3.29 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Aptose Biosciences Inc's stock holds steady at C$2.40.
The stock has a year-to-date increase of 18.81%, reflecting a positive trend despite recent changes.
Bull case
The acquisition by Hanmi Pharmaceutical could provide Aptose with better resources and capabilities. This support may lead to improved clinical development and new market opportunities.
Bear case
However, the transition following the acquisition may bring uncertainties. Investors should be cautious about potential operational challenges that can arise during this period.
Price Action Overview
Advertisement
Aptose Biosciences Inc's stock price has remained unchanged this week, closing at C$2.40. Over the past month, the stock has gained 9.09%, while year-to-date performance shows an increase of 18.81%. This stability may reflect investor sentiment as the company navigates its recent acquisition.
Recent Company News
The most significant recent development for Aptose was the completion of its acquisition by Hanmi Pharmaceutical on June 30, 2026. This acquisition marks a new chapter for the company, which may now have access to broader resources and support for its clinical programs. Investors are encouraged to follow how this transition unfolds in the coming months.
Technical Picture
From a technical standpoint, Aptose's stock is currently trading above its 50-day moving average (C$2.25) by approximately 6.4% and above its 200-day moving average (C$2.14) by about 12.3%. The stock’s 52-week range has been between C$1.41 and C$2.59, indicating that it is currently trading at 84% of its 52-week high. With a beta of 0.34, the stock exhibits lower volatility compared to the broader market. Recent trading volume was 2,945 shares, slightly below the 20-day average volume of 3,425 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
